A University of Queensland start-up company, developing a potential new treatment for obesity-related Liver Disease, has secured a seed investment of $1.3 million from IP Group, a UK-based intellectual property business. Jetra Therapeutics Pty Ltd is developing a treatment with the potential to reverse liver damage caused by Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic steatohepatitis (NASH). The company was founded on intellectual property developed by Mater Research in partnership with UQ (MRI-UQ) and licensed by UQ’s commercialisation company, UniQuest. The protein drug candidate was discovered by MRI-UQ Immunopathology Group Leader, Associate Professor Sumaira Hasnain, inflammation expert Professor Mike McGuckin,
Start-up gets backing for Liver Disease Treatment as seen on The Hippocratic Post.